A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Status:
Completed
Trial end date:
2016-01-20
Target enrollment:
Participant gender:
Summary
This is a 1-year base study with a 1-year extension to examine the effects of a new
experimental medication (odanacatib [MK-0822]) on postmenopausal osteoporosis. This study
will enroll approximately 375 postmenopausal women, and randomly assign them to 4 different
doses of odanacatib or to placebo. Measurements performed during the study include: bone
mineral density scans, spine x-rays, laboratory blood and urine tests, height measurements
and optional bone biopsies (at the end of 2 years).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Calcium Calcium Carbonate Cholecalciferol Vitamin D Vitamins